

Special Issue

New Insights in Radiotherapy

Message from the Guest Editor

This Special Issue “New Insights in Radiotherapy” will include reviews and original research on advances in radiation cancer treatments. We encourage scientists to submit manuscripts addressing any of the different aspects of this therapeutic option, such as: improvements in clinical strategies to enhance radiotherapy efficacy, new surgery and imaging techniques (e.g., MR-linacs or SBRT), the development of new radiosensitising agents (molecules, nanoparticles) able to increase the effect of radiation in tumour cells and/or radioprotector agents able to decrease the adverse effects on normal tissues. Novel insights in the identification of the molecular targets involved in the response to radiation, including cell survival and proliferation signalling pathways, the identification of mechanisms of tumour resistance to ionising radiation, the role of miRNAs and lncRNAs, the identification of changes in the transcriptome of both irradiated healthy and cancerous cells, or studies combining radiation and chemotherapy are of particular interest for this issue. Original investigations and comprehensive review articles are welcome.

Guest Editor

Dr. Carlos Martinez-Campa

Department of Physiology and Pharmacology, University of Cantabria, Santander, Spain

Deadline for manuscript submissions

closed (25 January 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/54050

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).